Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

Although China has made some progress, it still takes at least eight to nine months to get clinical trial approval there.

You may also be interested in...

Chinese Government Venture Firm Funds JV To Explore Early-stage Oncology Trials

SHANGHAI- Texas-based South Texas Accelerated Research Therapeutics recently announced that it will partner with Shanghai-based venture capital fund Cenova Ventures to form a joint venture to conduct early-stage oncology trials for pharma companies on both sides of the Pacific

Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals

SHANGHAI - China's slow drug approvals, which can take as long as two years, are expected to speed up considerably in the Chinese Year of the Rabbit. China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations

Korea FDA Prepares Guidelines On Phase 0 Clinical Trials To Draw More Early-stage Trials

SEOUL - Korea FDA is gearing up to release guidelines on Phase 0 clinical trials in the first half of next year under its broader ambition to draw more early-stage clinical trials to the country

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts